BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 14, 2003
View Archived Issues
XOMA Gets More Loan Money In Raptiva Deal With Genentech
Gearing up for an approval of the psoriasis drug Raptiva by year's end, Genentech Inc. and XOMA Ltd. have retooled their agreement, with the former financing the latter's development costs $80 million at a time. (BioWorld Today)
Read More
Celltech Gains Clear Advantage In Bid For Oxford GlycoSciences
Read More
Hopes Of Multiplying Monkeys To Mimic Human Disease Models Fail, Like Reproductive People Cloning
Read More
Ribozyme Regains Herzyme Control After Elan Backs Out
Read More
Other News To Note
Read More
Appointments And Advancements
Read More